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A B S T R A C T
The persistence of Staphylococcus aureus has been accredited to its ability to escape immune response via host cell
invasion. Despite the efficacy of many antibiotics against S. aureus, the high extracellular concentrations of
conventional antibiotics required for bactericidal activity is limited by their low cellular accumulation and poor
intracellular retention. While nanocarriers have received tremendous attention for antibiotic delivery against
persistent pathogens, they suffer daunting challenges such as low drug loading, poor retention and untimely
release of hydrophilic cargos. Here, a hybrid system (Van_DNL) is fabricated wherein nucleic acid nanogels are
caged within a liposomal vesicle for antibiotic delivery. The central principle of this approach relies on ex-
ploiting non-covalent electrostatic interactions between cationic cargos and polyanionic DNA to immobilize
antibiotics and enable precise temporal release against intracellular S. aureus. In vitro characterization of
Van_DNL revealed a stable homogenous formulation with circular morphology and enhanced vancomycin
loading efficiency. The hybrid system significantly sustained the release of vancomycin over 24 h compared to
liposomal or nanogel controls. Under enzymatic conditions relevant to S. aureus infections, lipase triggered
release of vancomycin was observed from the hybrid. While using Van_DNL to treat S. aureus infected macro-
phages, a dose dependent reduction in intracellular bacterial load was observed over 24 h and exposure to
Van_DNL for 48 h caused negligible cellular toxicity. Pre-treatment of macrophages with the antimicrobial
hybrid resulted in a strong anti-inflammatory activity in synergy with vancomycin following endotoxin stimu-
lation. Conceptually, these findings highlight these hybrids as a unique and universal platform for synergistic
antimicrobial and anti-inflammatory therapy against persistent infections.
1. Introduction
The rising incidence of persistent infections and multidrug-resistant
bacteria constitute a major threat to global health and has raised con-
cerns over the prospects of a post-antibiotic era [1]. A large fraction of
community and nosocomial infections are attributable to S. aureus and
its methicillin-resistant strain (MRSA), with significant percentages of
the global population notoriously being persistent (20%) or inter-
mittent carriers (60%) [2]. Treatment of S. aureus is especially chal-
lenging as the pathogen is able to escape immune response via host cell
invasion where it has life-long protection from antimicrobial therapy
[3]. Because many conventional antimicrobials have restricted in-
tracellular penetration or low retention, more than two-thirds of
prescribed antibiotics are ineffective and cause severe systemic toxicity
[4,5]. Treatment with sub-optimal dosing, not reaching bactericidal
intracellular concentrations enhances the risk for developing drug re-
sistant infections. There is therefore an urgent need to develop drug
delivery platforms that can enhance the efficacy of conventional anti-
biotics against intracellular infections.
Nanomaterial-enabled drug delivery systems have been extensively
explored to improve uptake, enhance targeting and bioavailability of
several drug molecules [6]. Among the many nanocarriers of interest,
core-shell drug carriers such as liposomes are among the most suc-
cessful commercialized antimicrobial therapeutics [7,8]. Despite their
success, low drug loading content, poor retention and untimely release
of hydrophilic cargos remain major roadblocks of liposomal products
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[9]. To improve drug loading, a popular approach via remote active
loading of drugs into preformed liposomes uses pH gradients and po-
tential differences across liposomal membranes [10]. However, this is
reserved for drugs with protonizable amines and is ineffective where pH
and ion gradients do not apply. Recent approaches to facilitate drug
accumulation via secure cargo loading within liposomes include smart
strategies to covalently functionalize cargos to cue responsive linkers
for site-specific drug release [11,12]. Nevertheless, such strategies re-
quire specific tedious covalent conjugations, toxic crosslinkers and
harsh purification steps. On the other hand, advancing trends within
nanomedicine using deoxyribonucleic acid based nanocarriers for in-
tracellular drug delivery has received much attention for its simplicity
and specificity [13,14]. Recent literature on the development of DNA
nanostructures (e.g. tetrahedrons and nanogels) demonstrate defined
control over hydrodynamic size/shape, with high payload capacity
reaching maximal efficacy, low toxicity, efficient intracellular delivery
and immune-modulatory applications [15–17]. These nanomaterials
are amenable to loading DNA-binding drugs via intercalation and
electrostatic interactions with high efficiency and drug efficacy
[18–21]. For instance, the high binding affinity between crosslinked
DNA nanostructures and antimicrobial peptides was recently exploited
for the topical treatment of S. aureus [22]. However, relying on re-
versible non-covalent electrostatic bonds for intracellular drug delivery
is highly prone to premature extracellular release which can compro-
mise performance [23]. Additionally, crossing the limits for drug
loading of cationic ligands (drug: DNA) is associated with complex
formation, precipitation and poorer intracellular penetration.
The development of antimicrobial drug delivery systems controlled
by the microenvironment of bacteria pathogens can be exploited to
induce or initiate antibiotic release [24]. Such virulence factors (e.g.
lipases and DNase) are produced in abundance by bacteria to impair
cell function and elicit host damage [25]. The exploitation of these
toxins has been widely reported as stimuli to trigger the release of
entrapped cargos from liposomes and DNA-based nanomaterials. For
instance, Yang and co-workers recently demonstrated an enhanced re-
lease of vancomycin from liposome coated mesoporous nanoparticles in
the presence of bacteria lipases [26]. Several other nanocarriers have
been shown to respond to bacterial lipases [27–29]. Pan and co-workers
studied the nuclease digestion of gemcitabine-containing DNA nanogels
over 24 h [30]. After incubating the nanocarriers in DNASE II, the
authors report an almost complete degradation of the nanogels using
PAGE analysis. Simultaneous detection and killing of S. aureus patho-
gens was also shown using DNA nanoscaffolds loaded with actinomycin
D [13]. The authors demonstrated degradation of the nanostructure in
response to DNase enzymes which was responsible for the release and
effective killing of the infectious bacteria. Hybrids developed by com-
bining these strategies can enable the fabrication of advanced anti-
microbial platforms with enhanced potency against bacterial infections.
Recently, Chen and colleagues developed a hydrogel enveloped li-
posomal nanostructures with high drug loading and enhanced delivery
of nucleic acids and proteins [31]. Inspired by this approach, we en-
visioned that non-covalent drug loading and subsequent entrapment of
nucleic acid nanogels within liposomal vesicles could facilitate high
encapsulation efficiency and enable “on-demand” release of cationic
drugs. In this study, we designed and fabricated nanostructured hybrid
system wherein nucleic acid nanogels are caged within a liposomal
vesicle for the intracellular delivery of vancomycin. We demonstrated
that by exploiting the non-covalent interactions between entrapped
DNA nanostructures and vancomycin, the hybrids achieved higher an-
tibiotic loading efficiencies than the liposomal controls. Acting as a
barrier to rapid drug loss, the hybrids sustained the release of vanco-
mycin under physiological conditions and, upon exposure to enzymatic
proteins, rapidly degrade to provide control over release kinetics in
microbial environments. Effective inhibition of planktonic and in-
tracellular S. aureus in a dose dependent manner was observed over
24 h in in vitro models of infection and the hybrids caused negligible
cellular toxicity over 48 h. Pre-treatment of macrophages with the
antimicrobial hybrid resulted in a potent anti-inflammatory activity in
synergy with vancomycin following endotoxin stimulation. Notably, the
potent anti-oxidant activity of the blank hybrids did not perturb the
oxidative stress mediated antibacterial mechanism of the antimicrobial
cargo. These findings underscore the versatility of the hybrid system as
an innovative platform for antibiotic loading and therapy against per-
sistent infections which can be adapted for other pathological condi-
tions and further developed as multifunctional co-delivery systems.
2. Experimental section
2.1. Fabrication and characterization of the hybrids
Blank and vancomycin-loaded DNA nanogels were prepared by
adopting a two-step annealing method, as previously published [15].
Briefly, the nanostructures were formed by mixing stochiometric con-
centrations of each single strand oligonucleotide (Integrated DNA
Technologies, Belgium) in 1× encapsulation buffer [32] (EB) (5 mM
Tris-HCL, 1 mM EDTA, 10 mM MgCl2, 10 mM NaCl) (Sigma Aldrich,
Norway) to achieve final concentrations of 1 μM (Y-SAB), 4 μM (Y-SAF)
and 6.5 μM (L-SAC) of the monomers, respectively. The samples were
hybridized at 95 °C and slowly cooled to 4 °C for 2.5 h. Thereafter,
equal volumes of the monomers were added to an equal volume of
buffer or vancomycin (Sigma Aldrich, Norway) to form the blank na-
nogel (DNG) or vancomycin loaded nanogel (Van_DNG) formulations.
The samples were heated at 95 °C and quickly cooled to 4 °C for 3.5 h.
The self-assembly of the nanostructures and formation of the nanogel
was confirmed using agarose electrophoresis (100 V for 45 min) and
imaged using the GelDoc XR+ (BIORAD, Norway).
Liposomes were prepared using standard techniques. Briefly, lipid
films were prepared using the thin-film hydration method by dissolving
pure soy phosphatidylcholine (Lipoid S100) (Lipoid GmbH,
Ludwigshafen, Germany) in methanol (Sigma Aldrich, Norway) and
placing the solution under vacuum at 45 °C [33]. After 1.5 h, the film
was rehydrated with blank buffer, DNG or Van_DNG to achieve a the-
oretical lipid concentration of 10 mg/mL. The solutions were extruded
5× through 800 nm, 400 nm and 200 nm polycarbonate membranes
(Sigma Aldrich, Norway) and stored at 4 °C [33]. The liposomes were
purified by dialysis against 1× EB buffer to remove the un-en-
capsulated drug and DNA using membranes with a cut-off of 12–14 kDa
(Thermo Fischer Scientific, Norway) and 1000 kDa (Thermo Fischer
Scientific, Norway) respectively. The samples were stored at 4 °C until
further used. The size distribution and zeta potential were determined
via dynamic light scattering (DLS) using the NanoZS Zetasizer (Mal-
vern) with standard settings [34]. The stability of the liposomes was
performed by monitoring changes in size,zeta potential and PDI.
For TEM measurements, the formulations were deposited on glow
discharged 200 or 400 mesh carbon-coated grids for 5 min and stained
with uranyless (Electron Microscopy Sciences, USA) for 10–40 s. The
samples were allowed to air-dry for 30 min and imaged using the
HT7800 (Hitachi, Japan) at 20–120 kV acceleration voltage equipped
with Morada digital camera.
2.2. Encapsulation efficiency and lipid content determination
The encapsulation efficiency (EE%) of vancomycin or DNA was
calculated using the equation:
= ×EE% (C /C ) 100%encap total
where Cencap refers to the measured concentration of vancomycin or
DNA obtained after dialysis and Ctotal is the concentration of vanco-
mycin or DNA in an equal volume of the formulations before dialysis.
Liposomal solutions were disrupted using methanol (90%v/v) and
the samples containing DNA were purified via centrifugation using
centrifugal filters (50 kDa) (Sigma Aldrich, Norway). The concentration
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of vancomycin was determined via UV absorbance (280 nm) (Agilent
8453, USA) with a pre-determined calibration curve using the flow-
through obtained.
To determine the EE% of DNA, the picogreen (Thermo Fischer
Scientific, Norway) assay method was used. After disruption with me-
thanol, 50 μL of picogreeen was added to an equal volume of the sample
and incubated for 5 min in the dark. The concentration of DNA was
then quantified using fluorescence (Ex. 480 nm, Em. 520 nm) mea-
surements. The lipid concentration of each formulation was also de-
termined via fluorescence using the phospholipid quantification kit
(Sigma Aldrich, Norway) by following the manufacturer's protocol (Ex.
535 nm, Em. 587 nm). All fluorescence measurements were performed
on Spark multimode microplate reader (Männendorf, Switzerland).
2.3. Binding affinity determination
The interactions between vancomycin and the DNA nanostructures
was studied in 1× EB by recording changes in UV absorbance. Briefly,
100 μg/mL of vancomycin and 1 μM of Y-SAF monomer was prepared.
The monomer was diluted two-folds and added to an equal volume of
vancomycin to achieve final concentrations of 0.5 μM to 0.0625 μM
DNA and 50 μM vancomycin. The spectra analysed using the plate
reader at 280 nm for vancomycin alone served as the control.
For Förster resonance energy transfer (FRET) assay, BODIPY la-
belled vancomycin (BODIPY-Van) (Fischer Scientific, Norway) was in-
cubated with Alexa-594 labelled DNA (IDT, Belgium) nanogel or Alexa-
594 labelled Y-SAF monomer at RT and excited at 435 nm. A reduction
in the donor emission at 514 nm with a corresponding increase in the
acceptor emission at 620 nm was indicative of FRET.
DLS was performed to monitor the changes in the hydrodynamic
size of Y-SAF monomer in the presence of increasing concentrations of
vancomycin in 1× EB.
2.4. In vitro drug release determination
The release profile of vancomycin from the formulations was ob-
tained using a vertical static Franz Diffusion Cell apparatus
(PermeGear, USA) equipped with a 5 mL acceptor chamber. The donor
chamber was loaded with 700 μL of Van_DNL with or without 1 mg/mL
Lipase (from wheat germ, ~0.1 U/mL) (Sigma Aldrich, Norway) and
mounted on a cellophane membrane barrier (Zellglas, Germany). As a
control, the release of vancomycin from the nanogels (Van_DNG) or
liposomal formulation alone (Van_L) was also studied. The receptor
chamber was filled with phosphate buffered saline (pH 7.4) and
maintained at 32 °C under constant stirring. Lipase sensitive release
profiles of the liposomes was studied by adding 5%v/v of 20 mg/mL
Lipase solution to achieve a final concentration of 1 mg/mL in the
donor chamber. Samples (500 μL) were withdrawn at predetermined
time points from the receptor chamber and then replaced with an
equivalent volume of fresh buffer. The concentration of vancomycin
released into the receptor chamber was determined via absorbance and
reported as the mean ± SD using triplicate readings (n= 3). At the end
of 24 h, the concentration of vancomycin remaining in the donor
chamber was quantified after disrupting the liposomes and removing
DNA [34].
2.5. Overnight culture growth assay
Bacterial viability was determined after exposure to the formula-
tions using standard broth dilution tests. Briefly, S. aureus (MSSA476)
(ATCC, USA) was grown in Mueller Hinton Broth (MHB) medium
(Sigma Aldrich, Norway) to the mid log phase and diluted in fresh MHB
to achieve a final bacterial CFU of 3 × 105 CFU/mL [35]. To each well
of a 96 well plate, 50 μL of OD-adjusted S. aureus was added to an equal
volume of formulations to achieve final vancomycin concentrations
ranging from 0.06 μg/mL to 4 μg/mL. The plates were incubated at
37 °C under continuous shaking (100 rpm) for 16 h and the bacterial
viability determined by measuring the optical density at 600 nm on a
Spark multimode microplate reader (Männendorf, Switzerland) to de-
termine the minimum inhibitory concentration (MIC). The percentage
reduction in bacterial cell viability was calculated of the growth control
group where bacterial cells were treated without the formulations. All
experiments were performed in triplicate.
2.6. Time kill assay determination
Time-kill curves were obtained by culturing S. aureus in the pre-
sence of the hybrid formulation, Van_DNL alone at 1 x MIC to 4 x MIC.
Bacterial cultures were prepared in MHB from bacteria grown to the
mid-log phase and then diluted to obtain a final inoculum concentration
of 3 × 106 CFU/mL. For each concentration, 500 μL of bacterial culture
was added to 500 μL of the formulations and incubated under con-
tinuous shaking of 100 rpm at 37 °C. At predetermined time points,
10 μL samples were taken at 0 h, 1 h, 2 h, 4 h, 8 h and 24 h, serially
dilute 10-fold to determine the number of viable bacteria. For controls,
bacteria growth was determined in the presence of MHB buffer alone.
The viable bacterial colonies were determined by plating 20 μL drops of
each dilution on MHB agar plates (Sigma Aldrich, Norway) in tripli-
cates. The plates were further incubated for 24 h. To quantify the
number of viable bacteria the following equation was used: Viable
count (CFU/mL) = dilution factor x [average number of colonies per
drop/ volume of drop (0.02 mL)]. The experiments were performed in
triplicates.
2.7. In vitro uptake and subcellular distribution
The intracellular trafficking profile of the Van_DNL in RAW 264.7
cells (Sigma Aldrich, Norway) was examined using confocal micro-
scopy. Raw 264.7 cells (passage 6–10) were seeded at a density of
1 × 105 cells per well in 8 well chambers (Thermo-Fischer, Norway)
and incubated for 24 h (37 °C, 5% CO2). After washing each well twice
with phosphate buffered saline (PBS) (Sigma Aldrich, Norway), the cells
were treated with the Van_DNL for 12 h. After 12 h, the cells were
washed with PBS, stained with Hoeschst 333342 (Thermo Fischer
Scientific, Norway) and incubated for 15 min. After 15 mins, the cells
were washed and incubated with LysoTracker Red dye (Thermo Fischer
Scientific, Norway) and imaged using the Zeiss LSM 800 confocal mi-
croscope (Germany).
2.8. Intracellular antimicrobial activity
To test the intracellular antimicrobial activity of the Van_DNL for-
mulation, RAW 264.7 cells (passage 6–10) were seeded into 12-well
plates at a density of 2.5 × 105 cells per well in DMEM HG (supple-
mented with 10% v/v Fetal Bovine Serum and 1% Pen/Strep) (Sigma
Aldrich, Norway) and incubated for 24 h (37 °C, 5% CO2). S. aureus was
grown to the mid-log phase in tryptic soy broth (TSB) (Sigma Aldrich,
Norway) broth. The cells were collected via centrifugation and then
diluted in PBS. After adjusting the bacteria concentration to
3 × 107 CFU/mL, S. aureus was diluted in DMEM (without Pen/Strep)
and added to each well at a MOI of 10. After infecting the cells for 30
mins, the cells were washed and incubated with DMEM (supplemented
with 2% v/v Fetal Bovine Serum) and gentamycin (100 μg/mL) for 1 h
to eliminate extracellular bacteria. The cells were washed and treated
with Van_DNL at doses of 1, 10 and 100 μg/mL for 18 h. After 18 h, the
cells were washed again and lysed using PBS containing triton X
(0.2%v/v) (Sigma Aldrich, Norway) for 30 mins to determine the in-
tracellular activity of the formulation. The lysed cells were diluted in
PBS and the number of viable bacteria enumerated by plating the ly-
sates on MHB agar plates. After 24 h, the number of viable counts were
determined by visually counting the cells and the loss in bacteria co-
lonies calculated as a percentage of the untreated control.
S. Obuobi, et al. Journal of Controlled Release 324 (2020) 620–632
622
2.9. In vitro cytotoxicity assay
The cytoxicity of Van_DNL was evaluated in murine RAW 264.7
cells (passage 6–10) over 48 h. Briefly, the cells were seeded at 6000
cells/well in 96-well plates and incubated for 24 h (37 °C, 5% CO2).
Thereafter, the cells were washed with PBS and incubated with in-
creasing concentrations of Van_DNL with and without vancomycin.
After 48 h incubation, the percentage cell viability was quantified using
MTT assay (Sigma Aldrich, Norway) by following standard protocols.
After incubating the cells with MTT solution (10 mg/mL) diluted in
DMEM (1:10) for 2 h, the cells were washed and the purple formazan
crystals dissolved with DMSO (100 μL) (Sigma Aldrich, Norway).
Absorbance readings were recorded at 570 nm and the number of viable
cells expressed as a percentage of the control.
2.10. Anti-inflammatory activity
To evaluate the anti-inflammatory activity of Van_DNL, RAW 264.7
cells (passage 6–10) were seeded in 24 well plates at 40,000 cells per
well and allowed to attach for 24 h (37 °C, 5% CO2) in DMEM HG
(supplemented with 10% v/v Fetal Bovine Serum and 1% Pen/Strep).
Afterwards the cells were pre-treated with the formulations in DMEM
HG (supplemented with 3% v/v Fetal Bovine Serum) for 24 h.
Thereafter, the cells were washed with PBS and stimulated with lipo-
polysaccharide (LPS; Escherichia coli O55:B5, Sigma Aldrich, Norway) at
500 ng/mL. After 12 h the media was collected for cytokine analysis. In
another set of experiments, the cells were allowed to attach for 24 h.
Thereafter, the cells were starved by incubating in DMEM HG (sup-
plemented with 3% v/v Fetal Bovine Serum) for another 24 h. The cells
were then washed with PBS and then co-treated with LPS and the for-
mulations for 12 h. The media was collected, centrifuged and the su-
pernatant collected for analysis.
After pre−/co- treatment with the formulation, the amount of IL-6
released was quantified to determine the anti-inflammatory activity of
the formulations using ELISA Kits (Thermo Fischer Scientific, Norway)
according to the manufacturer's guidelines.
2.11. Detection of ROS level
The Dichloro-dihydro-fluorescein diacetate (DCFH-DA) (Sigma
Aldrich, Norway) assay was used to determine reactive oxygen species
(ROS) production from the macrophage cells. Briefly, RAW264.7 cells
were pre-treated with Van_DNL as previously described for the IL-6
ELISA test. After treatment, the cells were stimulated with LPS for 12 h.
Thereafter the media was removed, the cells were washed and then
incubated with DCFH-DA for 25 min. The fluorescence intensity was
measured using the Spark multimode microplate reader (Männendorf,
Switzerland) to evaluate the ROX produced by the cells.
Fig. 1. Fabrication of DNA nanogels and binding studies. a) Gel electrophoresis of hybridized Y-SAF (Lane 1), Y-SAB (Lane 2), L-SAC (Lane 3) and DNA nanogel (Lane
4). b) Effect of increasing dsDNA (Y-SAF) on UV spectra of vancomycin (280 nm). c) Effect of vancomycin on UV spectra of dsDNA (L-SAC). d) FRET analysis with
Alexa-594 Y-SAF (acceptor) and BODIPY vancomycin (donor).
S. Obuobi, et al. Journal of Controlled Release 324 (2020) 620–632
623
2.12. Statistics
Data was represented as the mean standard deviations and analysed
using GraphPad Prism 8 (La Jolla, CA). The statistical significance
among the groups was determined using the two-sample student t-test
and one-way ANOVA analysis. Multiple comparisons were done using
Dunnett's test. The results were reported as statistically significant for
p < .05.
3. Results and discussion
3.1. Synthesis of the nanogels and characterization of their binding to
vancomycin
The formation of the DNA nanostructures and their self-assembled
nanogel products used in the preparation of Van_DNL was achieved via
self-assembly of complementary ssDNA sequences (Table S1). The
products were analysed using agarose gel electrophoresis as shown in
Fig. 1a. A single band was shown for the individual monomers (Lane
1–3) indicating the absence of side products and complete hybridiza-
tion of the strands (Fig. 1a). A smear band of higher molecular weight
products were observed (Lane 4) due to the slower migration of the
nanogel product than the individual monomers, an indication of the
self-assembly of the nanostructures to successfully form polydisperse
nanogels. This observation is similar to previous reports on oligonu-
cleotide rapid self-assembly of DNA nanostructures for nanogel fabri-
cation [36–38]. Moreover, the self-assembly of the nanogels offers a
simple and non-toxic strategy over other nanocarriers which rely on
chemical functionalization or are challenged by toxic initiators or long
synthesis time [29,39].
Next, the interactions between vancomycin and the DNA nanogels
was probed by measuring changes in the UV spectra of vancomycin and
dsDNA. As shown in Fig. 1b, gradual addition of the DNA nanos-
tructures resulted in a corresponding increase in absorbance bands
(hyperchromic effect) of vancomycin. A similar hyperchromic effect
was observed when vancomycin was added to the dsDNA (Fig. 1c). In
both instances a characteristic red-shift of 1–11 nm (vancomycin) and
2 nm (DNA spectra) was recorded indicating the presence of non-
covalent interactions (e.g. aromatic stacking) between vancomycin and
the dsDNA nanostructures. FRET (Fig. 1d) characterization of the mo-
lecular interactions between vancomycin and the nanostructures was
also investigated using BODIPY labelled vancomycin as the donor and
Alexa_594 labelled DNA as the acceptor. Changes in the fluorescence
intensity of BODIPY labelled vancomycin (2 μM) alone and in the
presence of increasing concentrations of Alexa_594 labelled DNA na-
nostructures was monitored by exciting the donor at 435 nm. A pro-
gressive increase in the acceptor fluorescence intensity at 620 nm
(dsDNA) and corresponding quenching of the donor fluorescence at
514 nm (vancomycin) was observed. There was approximately
87.60 ± 5.07% increase in fluorescence for the acceptor at the highest
concentrations of the nanostructures as a result of the resonance energy
transfer between the donor and acceptor. All together, these results
demonstrate the close proximity of the chromophores of vancomycin to
the bases of the DNA nanostructures attributable to aromatic stacking/
hydrogen bonding/ electrostatic/hydrophobic interactions and agrees
with reports on the main chemical driving forces for vancomycin-DNA
interactions [40,41]. For instance Kong and co-workers demonstrated
that vancomycin possessed the ability to promote the aggregation of
DNA using Rayleigh scattering and resonance nonlinear scattering (a
highly sensitive method) [40]. As the last-resort antibiotic for the
treatment of severe infections caused by gram-positive bacteria, our
observations further confirm that vancomycin can be efficiently in-
corporated into the hybrid system. Other considerations made include
that in comparison with previously trialed antimicrobial peptide L12
(MIC: 8 μM), the higher potency of vancomycin (MIC<1 μM) against S.
aureus is attractive when complexed with DNA thus, vancomycin was
used as the model drug [22].
3.2. Synthesis and characterization of Van_DNL
As shown in Fig. 2, Van_DNL were synthesized by following a three-
step self-assembly procedure. Firstly (step A), the monomeric nanos-
tructures Y-SAF (main scaffold), L-SAC (linker) and Y-SAB (terminating
unit) were synthesized individually, mixed together with vancomycin
(Van_DNG) or buffer solutions (DNG) and then hybridized to promote in
situ drug entrapment and nanogel formation (step B). Pre-formed lipid
films (step C) prepared using the thin-film method were then hydrated
with the DNA nanogels to obtain the antimicrobial hybrids (Van_DNL)
or blank hybrids (DNL).
To design a hybrid tailored against intracellular bacterial infections,
adequate control of size and surface charge is critical for uptake. We
selected the three nanostructures due to the relatively small size of the
nanogel construct reported to facilitated intracellular uptake [15]. To
prevent the formation of complexes of larger sizes at high concentra-
tions of vancomycin, we investigated the effect of antibiotic loading on
the size of the nanogels using DLS. As shown in Fig. 3a, we observed no
significant increase in the size of the nanogels below 2460 μg/mL of
vancomycin. Conversely, a significant increase in average size of the
nanogel from 76.73 ± 16.76 nm to 482.30 ± 40.53 nm (2460 μg/mL)
and 579.93 ± 57.46 nm (at 4920 μg/mL), respectively, was observed
clearly demonstrating the binding affinity between the DNA nanogels
and vancomycin.
Since we aimed to prepare hybrids of ~200 nm size, we then sought
to address the impact of drug concentration on the entrapment of the
Fig. 2. Development of antimicrobial hybrids. (A) Fabrication of antibiotic loaded nanogels through non-covalent electrostatic interactions in parallel with Watson
Crick base-pairing and (B) subsequent rehydration of lipid films (C) to produce the antimicrobial hybrids.
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DNA nanogel within the hybrid after extrusion by quantifying dsDNA.
Formulations prepared with three different concentrations of vanco-
mycin were selected for analysis. Soy phosphatidyl choline (SPC, >
94% purity), a neutral lipid, was chosen in the fabrication of Van_DNL
to prevent structural distortion of the nanogel which we hypothesized
could influence antibiotic entrapment. As shown in Fig. 3b, nucleic acid
entrapment efficiency was 83.78 ± 0.511% and 85.78 ± 1.47% for
Van_DNL at vancomycin doses of 640 μg/mL and 1280 μg/mL, re-
spectively. A significant reduction in nucleic acid entrapment to
55.61 ± 0.158% was observed above 1280 μg/mL stemming from the
formation of larger nanocomplexes which supports the DLS results.
Thus, we selected vancomycin dose of 1280 μg/mL for synthesizing
Van_DNL.
Next, to further characterize the nanogel, liposomal and hybrid
formulations, DLS was performed to determine the differences in size
and zeta potential. As shown in Fig. 3c, vancomycin loading into na-
nogel resulted in a significant size reduction (from 109.33 ± 9.66 nm to
86.23 ± 14.02 nm) and zeta potential (from −25.98 ± 0.39 to
−21.40 ± 1.01) for Van_DNG. This observation is attributable to the
neutralization of the anionic surface potential and condensation of the
nanogel. The subsequent entrapment of nanogel within the liposomes to
form the Van_DNL resulted in a significant increase in the hydro-
dynamic diameter in comparison to Van_L or Van_DNG formulations.
For instance, a significant change from 180.27 ± 0.67 nm (Van_L) to
225.20 ± 1.91 nm (Van_DNL) was recorded which clearly
demonstrates the entrapment of the DNA nanogel. Moreover, liposomal
vesicle shielded the highly negative surface charge of the nucleic acids
and resulted in a significant change in zeta potential from
−21.40 ± 1.01 to −0.60 ± 0.30 as shown in Fig. 3c. Additionally,
Van_DNL showed a narrow and homogenous (PDI: 0.20 ± 0.01) size
distribution compared to the Van_DNG formulation exhibiting a poly-
dispersity index of 0.50 ± 0.04 (Fig. 3d). Recent fabrication of DNA
coated mesoporous nanoparticles demonstrated a significant increase in
size from 191 ± 8 to 216 ± 25 nm due to the coated DNA layer [42].
The authors also reported a change in the surface potential for the
amino functionalize nanoparticles which became more negative fol-
lowing DNA functionalization. Their observations were similar to this
present work wherein the lipid bilayer coating resulted in an increased
size while maintaining a low PDI and good homogeneity. The neu-
tralized surface potential also provides a clear indication of the suc-
cessful nanogel coating.
Encapsulation efficiency (EE%) measurements were conducted to
compare the entrapment efficiency of vancomycin in the formulations.
As shown in Fig. 4a, Van_DNL displayed an EE % of 76.59 ± 3.44%
which was significantly higher than the Van_L control group
(64.64 ± 0.73%).
Comparatively, we observed no significant difference between the
lipid concentration in the two formulations. The observed increment in
EE % can be attributable to increased drug concentration in the lipo-
somal core due to the non-covalent binding of vancomycin to the
Fig. 3. Fabrication of hybrids and characterization of the antibiotic nanogels and hybrids. a) Effect of vancomycin on hydrodynamic diameter of the nanogels. b)
Effect of nanogel size on nucleic acid entrapment efficiency. c) Hydrodynamic diameter and zeta potential measurements of the formulations. d) Size distribution of
the vancomycin loaded hybrids, liposome and DNA nanogel formulations.
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nanogel.
Furthermore, UV spectra analysis showed a slight red shift of 2 nm
due to entrapment of vancomycin in nanogel (Fig. 4b) which dis-
appeared following Van_DNL preparation. Subsequent disruption of the
lipid bilayer with methanol resulted in the reappearance of the char-
acteristic peak due to the release of vancomycin from Van_DNL which
further supports the EE% results.
The morphology of Van_DNL was thereafter characterized by
transmission electron microscopy (TEM) as a final confirmation of na-
nogel encapsulation. As shown in Fig. 4c, the Van_L displayed a sphe-
rical morphology with a relatively clear core containing nanocrystals
(blue arrows) of low electron density potentially due to the self-ag-
gregation of vancomycin within the lipid bilayer (red arrow). Con-
versely, the core-shell structure of Van_DNL (Fig. 4d) displayed a darker
core (green arrow) due to negative staining of the entrapped DNA
alongside a corona which can be attributable to the nanogel entrap-
ment. Jiang and co-workers reported on the development of magnetic
nucleic acid delivery system composed of a lipidoid coating [43]. TEM
imaging revealed core shell nanosystem with complete and uniform
coating on the nanoparticle surface as observed in our work.
To evaluate the stability of the formulation upon storage, we
monitored changes in size of the formulations over 4 weeks. As shown
in Fig. 4e, significant changes in the size of Van_DNG were observed
over time. The significant changes in size can be attributable to the
large polydispersity index of the formulations which negatively affects
storage stability. Conversely, no significant difference in the hydro-
dynamic diameter and zeta potential was observed over 4 weeks and
over 2 months (Fig. S1) for Van_DNL. Furthermore, we also observed
that entrapment of vancomycin during the self-assembly of the nanogel,
as reported for hybrid fabrication, further improved the stability of the
formulation. This is because, the addition of vancomycin to nanogel
solutions after self-assembly (post-loading) before hydrating the lipid
films resulted in immediate aggregation of the liposomes upon storage
at 4 °C (Fig. S2). Several examples of nanoparticulate liposomal hybrids
have been developed to enhance stability and promote stimuli-re-
sponsiveness [44]. Under physiologic conditions, the encapsulation of
gold nanoparticles within high density lipoproteins for instance, re-
duced aggregation [45]. Additionally, enhanced stability was observed
when DNA was complexed with lipid coated gold nanoparticles
[46,47], which is in agreement with our stability results.
3.3. In vitro release of vancomycin from Van_DNL hybrids
To further explore the release profile of vancomycin from the for-
mulations under physiological conditions, in vitro drug release experi-
ments were conducted. As shown in Fig. 5a, approximately
59.17 ± 13.42% of vancomycin was released within 12 h from the
Van_DNG formulation. At 24 h, the total drug release was approxi-
mately 87.19 ± 8.61% for the nanogel formulation. Release of van-
comycin from the Van_L formulation achieved a total drug release of
43.89 ± 4.11 by 12 h and 73.21 ± 3.0% by 24 h. This observation is
attributable to the presence of vesicular structures in the liposomal
formulation that reduced the release rate of vancomycin. Next, vanco-
mycin release from Van_DNL was evaluated and shown to be sig-
nificantly slower, with approximately 30.84 ± 3.86% and
52.34 ± 9.45% released by 12 h and 24 h respectively. The significant
reduction in drug release from Van_DNL is attributable to the entrap-
ment of the DNA nanogels which agrees with DLS and TEM results.
Comparatively, slower release of entrapped doxorubicin from magnetic
nanoparticle coated DNA nanogels was shown with approximately 25%
released within 5 h which was enhanced in response to external stimuli
such as pH [42]. In our hybrid, a similarly slow release of vancomycin
Fig. 4. Drug entrapment and stability of the hybrids. a) Entrapment efficiency of vancomycin in the hybrids and liposomes. b) UV spectra measurement of entrapped
Van_DNG in the hybrids. c) TEM morphology of Van_L. d) TEM images of Van_DNL. e) Stability of the formulations at 4 °C over 4 weeks.
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was observed which is attributable to the lipid bilayer.
Enzyme sensitive nanocarriers are attractive platforms for devel-
oping “on-demand” systems against infectious agents as they selectively
induce therapeutic cargo release. Thus, to determine the enzyme re-
sponsive release profile for vancomycin from Van_DNL in comparison to
Van_DNG, the accumulated release of vancomycin was evaluated in
response to DNase or lipase. In Van_DNG, approximately 6933.3 ng/mL
of dsDNA was released after 24 h in the absence of DNase (Fig. 5b). A
significant increase in the released dsDNA to 12,900 ng/μL of dsDNA
was shown in the presence of 4 U/μL of DNase. Surprisingly, despite the
significant increase in dsDNA from the formulation, there was no sig-
nificant difference in percentage of vancomycin released from Van_DNG
was shown (Fig. 5c). On the contrary, when Van_DNL was incubated
with lipase, catalytic degradation of the lipid bilayer resulted in a
dramatic increase in vancomycin release. The cumulative release of
vancomycin reached 33.70 ± 0.07% of the total encapsulated drug
within 5 h in the presence of lipase compared to 16.91 ± 0.92 in the
absence of lipase (Fig. 5d). At 24 h, drug release was further accelerated
with approximately 84.97 ± 0.47% release in the presence of lipase
compared to 52.34 ± 9.45% released in the absence of lipase. These
findings demonstrate that release of vancomycin is better controlled
from the hybrid formulation wherein active enzymes such as lipases
secreted by pathogenic S. aureus could degrade the liposomal bilayer
and trigger rapid vancomycin release. It is well-known that the hy-
drolysis of phospholipids can be catalysed by lipases due to the pre-
sence of ester bonds [48,49]. Our observations are in good agreement
with previous studies wherein liposomal membranes were disrupted in
the presence of lipases to trigger the release of entrapped cargos
[50–53]. In the treatment of Helicobacter pylori, Thamphiwatana and co-
workers exploited the abundance of secreted phospholipases within
infection sites to develop a doxycycline loaded liposomal hybrid [54].
The authors demonstrated a significant increase (10× increase) in the
release of rhodamine B from the hybrids in the presence of 10 μg/mL
compared to 1 μg/mL of the enzyme. Additionally, six times increase in
antibacterial efficacy of the hybrids was observed compared to the
empty controls which was significantly reduced when a phospholipase
inhibitor was added. The higher responsiveness of this hybrid
(600–2400 U/mg lipase) in comparison to our system (0.1 U/mg) is
attributable to the greater enzymatic activity of the lipase used by the
authors. Despite the absence of control over vancomycin release in the
nanogel formulation, the responsive degradation of the dsDNA is ad-
vantageous considering its therapeutic advantage in Van_DNL and
highlights the dual responsiveness of the hybrid formulation to both
lipase and DNase; both of which are produced by S. aureus [22,29].
3.4. In vitro antimicrobial activity
After demonstrating the lipase triggered release of vancomycin from
Van_DNL, we examined the antibacterial properties of the hybrid for-
mulation against pathogenic S. aureus. Vancomycin is a mainstream
glycopeptide antibiotic that is reserved against resistant Gram-positive
infections such as methicillin resistant Staphylococcus aureus (MRSA)
[55,56]. We tested the antibacterial effect of the formulations against S.
aureus by monitoring changes in bacterial viability (OD 600 nm) after
Fig. 5. In vitro drug release. (a) Sustained release of vancomycin from the hybrids compared to liposomal and nanogel formulations. (b) Effect of DNase on release of
dsDNA from the nanogels over 24 h. (c) Effect of DNase on vancomycin release from the nanogels. (d) Controlled release of vancomycin from the hybrids in the
presence and absence of lipase.
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treatment with different doses of free vancomycin, the nanogel for-
mulation and the hybrid formulation. As shown in Fig. 6a, after 18 h,
the free vancomycin completely inhibited the growth of S. aureus at a
concentration of 1 μg/mL. Similar inhibitory effect was observed for the
nanogel formulation due to the faster release profile and demonstrates
that thermal hybridization conditions used in the fabrication of the
nanogel did not degrade the drug. For the hybrid formulations, ap-
proximately 33.45 ± 19.73% viability of the bacterial cells was ob-
served at 1 μg/mL and a higher concentration of 2 g/mL was required to
completely inhibit bacterial growth. This observation could be
Fig. 6. In vitro antibacterial activity, intracellular antibacterial activity and uptake studies. (a) Effect of the free vancomycin, vancomycin loaded nanogel and
vancomycin loaded hybrid formulations on bacterial cell viability measured at OD 600 nm after 18 h. (b) In vitro time kill kinetics of the vancomycin loaded hybrid
formulations at different doses over 24 h (red dotted line refers to limit of detection). (c) Intracellular uptake of the vancomycin loaded hybrid. Nuclei stained with
Hoechst, lysosomes stained with Lysotracker RED dye and hybrid stained with TopFluor dyes. (d) Intracellular antibacterial activity of the vancomycin loaded hybrid
formulations at different doses in S. aureus infected macrophage cell model over 24 h. (e) Intracellular antibacterial activity of the vancomycin loaded hybrid
formulations and free vancomycin in S. aureus infected macrophage cell model over 24 h. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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attributable to the sustained release of vancomycin from the hybrids
and is in good agreement with the in vitro release data. Of the multiple
enzymes produced by S. aureus during infections, lipases are widely
recognised for their relationship with bacterial virulence [57]. In lipase-
producing pathogens, growth conditions such as pH, inoculum volume/
bacteria density, incubation time and carbon source have been de-
monstrated to influence lipase production and activity [58]. For in-
stance, Salihu and colleagues reported that a directly proportional ef-
fect on lipase activity was observed due to the inoculum volume of the
bacteria [59]. Ilesanmi and co-workers observed a similar trend with
incubation time and showed maximum lipase activity after 12 h of in-
cubation [58]. The time dependent release of virulence factors from S.
aureus and low inoculum volume may account for the slower release of
vancomycin from the hybrid as observed by the higher bacteria cell
viability compared to the vancomycin loaded nanogel and free drug.
Next, we examined the time-dependent antibacterial activity of the
hybrid formulation at varying doses based on the MIC (1× MIC to 8×
MIC) and using a higher bacteria inoculum. As shown in Fig. 6b, a si-
milar onset of action was observed for 2× MIC, 4× MIC and 8× MIC
doses. A time dependent reduction in bacterial CFU was observed at all
doses of the hybrid formulation for the first 8 h. For instance, for the
4× MIC hybrid formulation, approximately 0.6-log, 1.9-log, 3.7-log,
5.0-log and 7.5-log reduction in CFU was observed at 1 h, 2 h, 4 h, 6 h,
and 8 h respectively. A concentration dependent reduction in CFU was
also observed after 8 h, with approximately 3.9-log, 4.7-log, 5.0 log and
5.2-log reduction in CFU for the 1×, 2×, 4× and 8× MIC con-
centrations of the hybrid. After 24 h, no detectable colonies were seen
for the 4× (7.5-log) and 8× (7.5-log) MIC formulations demonstrating
the in vitro efficacy of the hybrid formulation against planktonic S.
aureus.
3.5. Intracellular antimicrobial activity and uptake of the hybrids
Many antibiotics exhibit poor efficacy against persistent infections
due to their limited intracellular penetration and poor accumulation.
This restricted intracellular efficacy increases the risk of recurring in-
fections thus, to test whether the hybrids could be used in treating in-
tracellular infections, we tested their intracellular penetration in
RAW264.7 cells. The Top-Fluor labelled Van_DNL was incubated with
the cells and confocal microscopy images captured. The results revealed
that Van_DNL was internalized by macrophage cells within 12 h of
incubation as shown in Fig. 6c and Fig. S3. Further investigation of the
uptake mechanisms revealed that following uptake, Van_DNL was as-
sociated with intracellular endosomes/lysosomes as confirmed by the
colocalization with the red fluorescence of the LysoTracker Red Stain
(Fig. 6c) showing that the hybrid is internalized via an endocytosis
driven mechanism. Moreover, the confocal images also revealed that
uptake of the intact Van_DNL given the presence of a Hoechst-stained
core (Fig. S4) which is attributable to the presence of the DNA nanogel
and is advantageous for achieving intracellular antimicrobial and anti-
inflammatory activity. According to current knowledge, the ideal
physicochemical properties of nanocarriers suited for efficient cellular
uptake varies with cell type [60]. Of nanocarriers composed of neutral,
cationic or anionic charges with sizes from 50 nm to 800 nm that have
been trialed, greater uptake has been observed with smaller liposomal
nanoparticles (85 nm). However, several studies have shown that the
immune system generates a stronger reaction with particles less than
100 nm and that uptake into mononuclear phagocyte system (MPS)
cells can be improved by increasing nanocarrier size with optimal sizes
of 200 nm reported [61]. While, carriers with cationic and anionic
surface charges have been shown to be associated with efficient cellular
uptake, the cytotoxicity of cationic nanocarriers limits their clinical use
[62]. On the other hand, repulsive forces are imminent between the
anionic liposomes and the DNA nanogels. In comparison to recent re-
ports, Yao and colleagues investigated the intracellular delivery of
magnetic DNA nanogels with similar size distribution (216 ± 25 nm)
[42]. Greater uptake efficiency was observed after 12 h and 24 h which
was comparable to the hybrids.
The intracellular antimicrobial activity of Van_DNL was evaluated
by examining the survival of intracellular S. aureus after treatment with
different doses of the formulation and to further reveal that the hybrid
could release its drug content in infected cells. We used S. aureus in-
fected Raw264.7 cells, a murine macrophage cell line, and evaluated
the intracellular survival of S. aureus. Treatment with Van_DNL
achieved a concentration dependent reduction in the intracellular
bacteria growth after 24 h of incubation as shown in Fig. 6d. The blank
hybrid formulation, DNL had no inhibitory effect on the bacteria
growth and was comparable to the placebo control (Fig. S5). In-
tracellular bacterial infection within the cells after eliminating extra-
cellular bacteria for DNL after 24 h was shown to be approximately
108.11 (n = 8). All concentration of Van_DNL resulted in significant
reduction in bacteria CFU. At 1 μg/mL absolute concentration of
Van_DNL, a 2.35-log significant reduction in bacteria CFU was ob-
served. It is worth noting that, treatment with the free drug resulted in
only 0.21-log reduction in CFU at this concentration of vancomycin
(Fig. 6e) demonstrating the superior antimicrobial activity of Van_DNL.
At higher concentrations of 10 μg/mL and 100 μg/mL Van_DNL, a 4-log
and 4.5-log reduction in bacterial CFU respectively, was observed
which corresponds to 99.99% inhibition in bacteria growth in-
tracellularly. Evaluation of the extracellular bacteria revealed a sig-
nificant reduction in extracellular bacteria with no viable bacteria co-
lonies in comparison to the controls at 100 μg/mL dose of the hybrid
(Fig. S6). The dose dependent reduction in intracellular bacteria ob-
served is attributable to the intracellular release of entrapped vanco-
mycin which agrees with the results from the in vitro release and time
kill kinetics. Moreover, the results clearly demonstrate that Van_DNL
could be delivered intact into macrophage cells, release encapsulated
vancomycin to efficiently kill intracellular S. aureus. We observed no
significant difference between the potency of Van_L and the Van_DNL
(Fig. S7).
3.6. Biocompatibility, anti-inflammatory and anti-oxidant effect of the
hybrid
We then evaluated the biocompatibility of the blank and vanco-
mycin loaded hybrid formulations in RAW264.7 cells. As shown in
Fig. 7a, treatment with Van_DNL resulted in more than 70% cellular
viability demonstrating the non-toxicity of the formulations according
to ISO criteria [63]. After 48 h the observed cellular viability was
80.16 ± 6.2% (12.5 μg/mL), 83.0 ± 11.77% (25 μg/mL),
95.25 ± 14.02% (50 μg/mL) and 89.79 ± 7.90% (100 μg/mL) for the
various concentrations tested. Treatments with equal volumes of DNL
resulted in cell viabilities between 99.99 ± 23.40% and
118.17 ± 19.75% demonstrating that the hybrid formulations did not
cause significant toxicity to the cells which is attributable to the bio-
compatibility of the DNA nanostructures/ natural phospholipids and
their degradation products [64,65]. The observed high cytocompat-
ibility of the hybrids is in good agreement with similar nano-constructs.
For instance, Ternullo and colleagues studied the effect of Lipoid S
based liposomes on human foreskin fibroblasts and human im-
mortalised keratinocytes [34]. The authors reported increased viability
in these cell lines after 24 h of treatment. Recently, Thelu and co-
workers also showed negligible toxicity of DNA hybrid nanogels against
Ramos, HeLa and CCRF-CEM cells [66]. Using the CCK8 assay, Mao and
colleagues treated human dermal fibroblasts with DNA tetrahedral
nanostructures for 24 h [67]. The authors revealed that the cell viability
significantly increased and peaked at 250 nM (>100%). These high cell
viabilities have been reported by several other authors [22] which
agrees with our results.
Several lines of evidence suggest that inflammatory response to
bacterial infection can be due to bacterial cell components such as li-
popolysaccharides (LPS), lipoteichoic acid (LTA) and peptidoglycan
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(PepG) which induce inflammation [68]. Thus, to better understand the
effect of the hybrid on inflammatory response, we established an LPS
activated macrophage cell models using RAW264.7 cells. The cells were
either pre-treated with the formulations prior to LPS stimulation (pre-
treatment) to determine if they could function as a preventive strategy
or treated together with LPS (co-treatment) to determine if they could
be used minimize inflammation. We compared the inflammatory re-
sponse of the blank nanogel, vancomycin loaded liposomal and van-
comycin loaded hybrid formulations by measuring changes in IL-6
production. As shown in Fig. 7b, LPS stimulation caused a significant
increase in IL-6 production. Pre-treatment of the macrophage cells with
the DNL prevented this inflammatory response, resulting in approxi-
mately 66.67 ± 21.19% reduction in IL-6 release (p < .01).
This observation is attributable to the potent anti-inflammatory
activity of the DNA nanostructures and is in good agreement with
previous studies [16,22]. Treatment with the Van_L resulted in only
36.51 ± 13.59% reduction in IL-6 release which was significantly lesser
than DNL. This observed is attributable to the reported anti-in-
flammatory activity of vancomycin [69].Van_DNL treatment resulted in
55.14 ± 14.45% reduction in IL-6 release (p < .01), which was sig-
nificantly greater than the observed reduction for Van_L (p < .05).
These results further indicate that Van_DNL nanocarriers potentiated
the anti-inflammatory activity of the cargo and highlight its synergistic
anti-inflammatory efficacy. Co-treatment of the cells with Van_DNL
during endotoxin stimulation, similarly exerted a potent anti-in-
flammatory effect with 45.94 ± 5.29% (Fig. 7c) reduction in IL-6
production which notably demonstrates that the hybrid formulation
can be used as an immune modulatory agent. S. aureus infections are
commonly associated with bacterial skin infections, bacteraemia,
peritonitis and septic shock [70]. The release of potent pro-in-
flammatory cytokines such as tumour necrosis factor alpha and inter-
leukin-6 causes severe inflammatory responses during S. aureus infec-
tion. This overwhelming uncontrolled inflammation (cytokine storm)
causes multi-organ failure which is the hallmark of Staphylococcal toxic
shock syndrome [70]. Antibiotics such as vancomycin are considered as
one of the main measures in eradicating the pathogen. In addition to
reducing bacteria growth, vancomycin has been shown to substantially
decrease inflammatory markers such as TNF-a and IL-6 [69]. In this
study, we demonstrated that while the use of liposomal vancomycin
alone led to a significant reduction in IL-6 production, this was to a
lesser extent that the anti-inflammatory activity achieved with the DNA
nanogel. In line with growing interest in crosslinked DNA nanos-
tructures as anti-inflammatory agents, a recent study by Zhang and co-
workers showed that pre-treatment with tetrahedral DNA
Fig. 7. In vitro biocompatibility, anti-inflammatory and anti-oxidant activity of the hybrid. (a) Cytocompatibility of the blank and vancomycin loaded hybrid
formulation against RAW264.7 macrophages over 48 h. (b) In vitro anti-inflammatory activity of the blank hybrid formulation, vancomycin loaded liposomal and
vancomycin loaded hybrid formulations after pre-treatment in LPS stimulated macrophages. (c) In vitro anti-inflammatory activity of the vancomycin loaded hybrid
formulations after co-treatment in LPS stimulated macrophages. (d) In vitro effect on ROS production of the blank hybrid formulation, vancomycin loaded liposomal
and vancomycin loaded hybrid formulations after pre-treatment in LPS stimulated macrophages.
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nanostructures in macrophages resulted in a significant reduction in IL-
6 production (p < .01) after 24 h [16]. Similarly, our previous work
demonstrated reduced LPS induced inflammation (22.8 ± 9.15%) in
macrophages with crosslinked DNA nanostructures [22]. This ob-
servation was clinically significant as it translated into rapid enhance-
ment of wound closure in murine mouse models. Thus, we hypothesized
that the best therapeutic can be offered by the combination of the na-
nocarriers with antibiotics. Gao et al. recently developed a peptide‑gold
nanoparticulate hybrid and examined their anti-inflammatory activity
[71]. In vitro, the authors demonstrated a potent inhibitory activity
(p < .01) of the hybrids on downstream cytokine production in THP-1
cell derived macrophages. The most potent hybrid prolonged the sur-
vival of mice experiencing lethal LPS challenge via reduced lung in-
flammation and by alleviating diffuse alveolar damage. The observed
comparable potent synergism (p < .01) of the hybrid thus paves way to
address the clinical manifestation of inflammation.
Next, the antioxidant effect of Van_DNL was evaluated by mon-
itoring oxidative stress as a function of reactive oxygen species (ROS)
and the changes in the DCFH-DA fluorescent probes. As previously re-
ported, the production of ROS oxidizes the nonfluorescent DCFH-DA
probe to emit a green fluorescence [72]. As shown in Fig. 7d, LPS sti-
mulation resulted in a significant increase in ROS production with a
quantified fluorescence intensity of 42,046 ± 243.24. Pre-treatment
with DNL led to a significant reduction in ROS production and corre-
sponding fluorescence intensity of 27,241.5 ± 912.87. Conversely, we
recorded a fluorescence intensity of 50,429 ± 1288.35 for Van_L at-
tributable to the release of vancomycin, which is known to increase
intracellular ROS production as a part of its mechanism of action
against pathogenic bacteria [73]. Similarly, treatment with Van_DNL
resulted in approximately 44,316 ± 5027.5 release of ROS which was
not significantly different from the liposomal formulation. These results
clearly confirm the intracellular release of vancomycin from Van_DNL
and also demonstrate that, the potent antioxidant effect of the DNL does
not diminish the ROS mediated antibacterial activity of vancomycin in
vitro.
4. Conclusion
An innovative hybrid formulation, Van_DNL, composed of DNA
nanogels encapsulated in liposomal vesicles was fabricated as a uni-
versal loading platform for the intracellular delivery of antibiotics. The
self-assembly of the DNA nanostructures, loading of vancomycin via
non-covalent electrostatic interactions and subsequent hydration of a
lipid film endowed the hybrid formulation with an anti-inflammatory
DNA nanogel core and “on-demand” release feature imparted by the
lipid bilayer. The binding affinity between the DNA nanostructures and
vancomycin was shown to significantly increase the antibiotic loading
and resulted in a relatively slower release profile than the liposomal or
nanogel formulations alone. We demonstrated enzyme potentiated re-
lease of vancomycin from Van_DNL in response to lipase enzymes whilst
DNase treatment resulted in a faster degradation of the nanostructures
but not vancomycin. In vitro antibacterial activity of Van_DNL demon-
strated a dose dependent and time-dependent reduction in CFU of
planktonic bacteria. The intracellular uptake of Van_DNL was shown to
be via an endocytosis mediated mechanism which translated into a
significant reduction in intracellular and extracellular bacterial CFU in
a dose dependent manner. Furthermore, the intracellular transport of
Van_DNL resulted in a significant anti-inflammatory activity in LPS
treated raw macrophages which was synergistic with the anti-in-
flammatory activity of vancomycin. Finally, we demonstrated that the
potent anti-oxidant effect of the blank hybrid, DNL, did not disrupt the
ROS induced mechanism of the antimicrobial cargo. Our results clearly
highlight the tremendous potential of the hybrid as an innovative an-
tibacterial nanocarrier and a powerful multifunctional co-delivery
platform which can be broadly applied against persistent infections. For
future directions implementing pathogen and cell targeting in clinical
models of infection/inflammation and demonstrating potency against
more virulent strains using functionalized hybrids will be explored.
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